Intercept Pharmaceuticals 3Q 2016 Earnings Presentation

Intercept Pharmaceuticals' third-quarter 2016 earnings presentation covering the commercialization of Ocaliva® for primary biliary cholangitis (PBC) in the U.S. and regulatory progress internationally, along with financial and operational updates. The presentation outlines the company's U.S. launch strategy, international expansion plans, and adjusted operating expense guidance.